Business Wire

Shionogi, Active Citizenship Network and MEPS Advocate for Urgent Policy Implementation in EU Member States at EU Parliament Event to Address the Growing Threat of Antimicrobial Resistance

Share

Shionogi & Co., Ltd. and its European subsidiary, Shionogi B.V. (hereafter "Shionogi"), held an event at the EU Parliament last week in the run-up to World Antimicrobial Awareness Week, joining forces with MEPs, Active Citizenship Network and MEPs Interest Group on "European Patients' Rights & Cross-Border Healthcare" to discuss initiatives to tackle AMR. The event reinforced the need for urgent attention and collaboration from pharmaceutical companies, policy stakeholders and governments to bring about policy change and innovation to address this growing issue.

The European Health Union has declared AMR one of its top three priority health threats in the EU requiring urgent attention and action. Within the context of the revision of the Pharmaceutical Legislation and the planned European Council Recommendations on AMR taking place in Q4 2022, the event brought together high-level European policymakers to discuss the innovation framework for the development of new antibiotics based on concrete examples of initiatives conducted by national health authorities to fight AMR. The event also explored collaborative and governance models to achieve better implementation of actions and best practices for a holistic AMR approach.

“The meeting was crucial to increase awareness of Antimicrobial Resistance and the need for new innovations to address unmet needs. I’m calling on patient organisations, industry, the European Commission, academia, and healthcare professionals to work together to drive policy change and put in place a common response to this increasing societal challenge,” said MEP Aldo Patriciello.

"The inclusion of the AMR within the work programme of the incoming Sweden Presidency of the Council of the EU and the prioritisation of the topic by the European Health Emergency Preparedness and Response Authority (HERA) give the opportunity to advance policy action to improve stewardship, surveillance of resistance patterns across Europe and incentivise innovation. These actions should be fully integrated into One Health Strategies providing solutions for human, animal and environmental health. The involvement of civic society and patient advocacy groups is also crucial in the development and implementation of AMR National Plans" commented Mariano Votta, Director of Active Citizenship Network, the EU branch of the Italian NGO Cittadinanzattiva.

MEP Fabio Massimo Castaldo also affirmed the importance of developing a predictable regulatory environment to incentivise private investments in new antibiotics, in addition to setting up rapid procurement and purchase mechanisms for crisis-relevant medical countermeasures to respond to emerging threats and better prepare European health systems. He stated that “with the adoption of the Global Health Strategy and Pharmaceutical Legislation Review, the time to act is now, and as Members of the European Parliament, we will thoroughly review these proposals to ensure it meets the objective and ambition that are needed.”

In 2019, bacterial AMR was directly responsible for 1.27 million deaths and associated with nearly 5 million deaths.2 Future projections for the impact of unresolved AMR are as high as 10 million deaths per year by 2050.3 Antibiotics are crucial for every aspect of modern-day healthcare, from common surgeries to chemotherapy and organ transplants. Unless urgent action is taken, we could face a future in which a lack of effective antibiotics could make routine medical procedures dangerous, make more complex interventions and procedures impossible, and reduce our ability to respond to outbreaks of infectious diseases. Tedros Adhanom Ghebreyesus, Director General at the World Health Organization (WHO) has called it a ‘slow tsunami that threatens to undo a century of medical progress’.

We know that incentivising innovation is critical in order to stimulate antimicrobial R&D and a pipeline of new and effective antibiotics, and this is necessary at both a European and local country level. We have seen specific examples of successful models which have been implemented in European countries and urge other EU member states to follow suit and consider similar incentives to help address the challenges faced in bringing novel antibiotics to market,” commented Mark Hill, Senior Vice President, Global Head of Value and Access, Shionogi.

While developing antibiotics is a long, costly and uncertain process, commercialisation can also be challenging. Once launched, understandably, there is often a low frequency of use driven by the need for stewardship to prevent resistance development. Low use leads to limited revenues, which in turn restricts continued commercialisation and new product research. As a result of these economic challenges, many large pharmaceutical companies are no longer active in the development and commercialisation of antibiotics, and several smaller biotech companies have filed for bankruptcy. Shionogi strongly supports the introduction of new incentives, funding and value assessment models for reimbursement to restore a viable commercial market to address the economic challenge faced in bringing novel antibiotics to market, whilst promoting stewardship.

Shionogi is committed to maintaining the momentum and leveraging collaborations with civil society, policymakers, industry, academia, and healthcare professionals to champion innovation to collectively turn the tide in the fight against AMR.

Antimicrobial resistance (AMR)

Antimicrobial resistance (AMR) is a major health burden which urgently needs to be addressed. Infections caused by carbapenem-resistant Gram-negative bacteria are often associated with a high mortality rate.3 If no action is taken, antibiotic resistance is predicted to kill 10 million people every year by 2050, at a cumulative cost to global economic output of 100 trillion USD.3

Shionogi’s commitment to fighting antimicrobial resistance

Shionogi has a strong heritage in the field of anti-infectives and has been developing antimicrobial therapies for more than 60 years. Shionogi is proud to be one of the few large pharmaceutical companies that continues to focus on research and development in anti-infectives. The company invests the highest proportion of its pharmaceutical revenues in relevant anti-infectives R&D compared to other large pharmaceutical companies.4

For more information please refer to: https://www.shionogi.com/global/en/sustainability/amr.html

About Shionogi
Shionogi & Co., Ltd. is a 142-year-old global, research driven pharmaceutical company headquartered in Osaka, Japan, that is dedicated to bringing benefits to patients based on its corporate philosophy of “supplying the best possible medicine to protect the health and wellbeing of the patients we serve.” The company currently markets products in several therapeutic areas including anti-infectives, pain, CNS disorders, cardiovascular diseases and gastroenterology. Shionogi’s research and development currently target two therapeutic areas: infectious diseases, and pain/CNS disorders.

For more information on Shionogi & Co., Ltd., please visit https://www.shionogi.com/global/en/

Shionogi B.V. is the European headquarters of Shionogi & Co., Ltd. For more information on Shionogi B.V., please visit www.shionogi.eu.

Forward-Looking Statements
This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

© 2022 Shionogi Europe. All Rights Reserved.

References

1 Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399:629-655. doi: doi.org/10.1016/ S0140-6736(21)02724-0. Available online: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02724-0/fulltext. Last accessed November 2022.

2 O’Neill, J. et al. Review on antimicrobial resistance. Tackling drug-resistant infections globally: final report and recommendations. 2016 https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf Last accessed November 2022

3 Perez F, et al. ‘Carbapenem-Resistant Enterobacteriaceae: A Menace to our Most Vulnerable Patients’. Cleve Clin J Med. Apr 2013; 80(4): 225–33

4 Antimicrobial Resistance Benchmark 2021.https://accesstomedicinefoundation.org/media/uploads/downloads/61ee760d03810_Antimicrobial%20Resistance%20Benchmark%20report%202021.pdf Last accessed November 2022

Job code: NP-EU-FDC-0398
Date of preparation: November 2022

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For further information, contact:
Shionogi B.V.
Jo Taylor
Executive Director, Corporate and Government Affairs
jo.taylor@shionogi.eu
Havas SO Media Contact
Nicola Lilley
Associate Director
+44 (0)20 3196 9912
Nicola.lilley@havasso.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Italian Tennis Star Jasmine Paolini Joins Amazfit as Latest Athlete Ambassador18.2.2025 17:00:00 EET | Press release

Amazfit, a leading global smart wearables brand owned by Zepp Health (NYSE: ZEPP), today announced the signing of Italian tennis sensation and World No. 4 Jasmine Paolini as its newest global athlete partner. As part of the multi-year agreement and official smart wearable partnership, Paolini will represent Amazfit by wearing the Amazfit logo and smartwatch on court and the brand’s fitness wearables, including Helio Ring, to track sleep and athletic recovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218222601/en/ Italian Tennis Star Jasmine Paolini Joins Amazfit as Latest Athlete Ambassador (Photo: Business Wire) Paolini is the current Italian No. 1 and highest-ranked Italian singles player in WTA history. She reached both singles and doubles finals at the 2024 French Open and was a singles finalist at 2024 Wimbledon. Additionally, Paolini is the reigning Olympic gold medalist in doubles and holds two WTA singles an

G2 Risk Solutions Acquires ZignSec AB for More Holistic Risk Management18.2.2025 16:06:00 EET | Press release

G2 Risk Solutions (G2RS), a leading provider of risk management solutions in the financial sector, is announcing the acquisition of one of its affiliated companies of ZignSec AB (ZignSec). This marks a significant step forward in G2RS’ mission to deliver comprehensive, technology-driven compliance and risk solutions to regulated businesses worldwide. ZignSec AB provides cutting-edge identity verification solutions and owns Web Shield, a leader in merchant due diligence services, and Wyzer, a business process optimization and automation specialist. The collaboration among the three companies is expected to enable G2RS to enhance its portfolio of services and broaden its reach into critical areas of risk and compliance management globally. With this move, G2RS aims to strengthen its ability to serve highly regulated sectors, including financial institutions such as banks, lenders, creditors, merchant acquirers, supervisory entities, and internet platforms. “This is a pivotal moment for o

Cymulate Reveals Next-level AI Automation for Threat Exposure Validation18.2.2025 16:00:00 EET | Press release

Cymulate, the leader in threat exposure validation, today announced the next evolution of the company’s flagship security validation platform. As a pioneer and market leader for breach and attack simulation (BAS) and automated red teaming, Cymulate continues to innovate with automation and artificial intelligence (AI) to deliver the most advanced and easiest-to-use threat exposure validation on the market. At a time when attackers are deploying more advanced tactics than ever, the Cymulate Exposure Validation Platform leverages the power of AI to give every blue and red teamer the automation and accessibility to validate and remediate threat exposure and optimize security. Exposure validation helps organizations go further than traditional solutions like BAS and automated penetration testing. By embracing the CTEM strategy, security teams can validate their exposure according to their defined threat scope, prioritize contextually according to their specific security strategy, and mobil

Bluefin Achieves Girocard Certification for the Newland Payment Technology N950 AIO smartPOS18.2.2025 16:00:00 EET | Press release

Bluefin has achieved the German Banking Industry Committee’s (GBIC German: Deutsche Kreditwirtschaft) Girocard certification on the Newland NPT N950 AIO smartPOS terminal. This certification enables German merchants to adopt next-generation SmartPOS devices while simplifying Girocard payment acceptance through Bluefin’s TECS Engine, a global payments platform. Bluefin’s TECS Engine provides omnichannel payment solutions to Acquirers, Payment Service Providers, POS system providers, Independent Software Vendors (ISVs) and other merchant aggregators around the globe offering a cloud-based Payments Platform-as-a-Service, including Bluefin’s payment and data security solutions, P2PE and universal tokenization. As the leading debit card in Germany, Girocard conducted 7.5 billion transactions in 2023. With Girocard certification on the Newland N950 AIO smartPOS terminal, the German market will benefit from an open platform with access to new generations of SmartPOS devices and streamlined Gi

Wooptix Secures Over €10 Million in Series C Funding Led by Samsung Venture Investment Corporation and Spanish Society for Technological Transformation18.2.2025 16:00:00 EET | Press release

Wooptix, a leader in semiconductor metrology leveraging wavefront phase imaging technology, has raised over €10 million in a Series C funding round. The round was led by Samsung Venture Investment Corporation and Spanish Society for Technological Transformation (SETT) with participation from existing investors, including the European Innovation Council Fund (EIC Fund), Intel Capital, MONDRAGON Corporation, and TEL Venture Capital, Inc. “The investment allows us to push the boundaries in resolution quality within the semiconductor technology landscape,” said José Manuel Rodriguez Ramos, CEO of Wooptix. “Continued support from our investors has allowed us to introduce our semiconductor metrology Fabtool to global markets and deliver innovative solutions to an international customer base.” The surging demand for AI has placed unprecedented pressure on the semiconductor manufacturing industry to produce increasingly complex and miniaturized chips. Traditional tools often fall short of the

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye